A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformin

Registry ID

EUCTR2006-001219-31

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2006-09-08

Completion date

2007-10-02

Last update

2026-08-16

Conditions

• Type II Diabetes

Summary

1. To demonstrate the effect of vildagliptin on the incretin mediated enhancement of insulin secretion (75 g oral glucose vs. matched i.v. glucose) in patients with T2DM treated with metformin by testing the hypothesis that the improvement of the incretin effect assessed as C-peptide IAUC(0-4hr) with vildagliptin 100 mg qd is superior to that with placebo after 2 weeks of treatment.

Locations

• , , Germany

Related clinical trials

• The GRoceries Aimed at Increasing Nutrition Study
• Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
• Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
• Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
• Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.

View on source registry